bluebird bio Stock Price, News & Analysis (NASDAQ:BLUE)

$201.80 30.65 (17.91 %)
(As of 12/11/2017 04:00 PM ET)
Previous Close$171.15
Today's Range$194.60 - $222.03
52-Week Range$60.95 - $222.03
Volume5.12 million shs
Average Volume843,362 shs
Market Capitalization$9.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.08

About bluebird bio (NASDAQ:BLUE)

bluebird bio logobluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:BLUE
CUSIPN/A
Phone+1-339-4999300

Debt

Debt-to-Equity RatioN/A
Current Ratio9.88%
Quick Ratio9.88%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.16 million
Price / Sales1,501.38
Cash FlowN/A
Price / CashN/A
Book Value$21.42 per share
Price / Book9.42

Profitability

Trailing EPS($7.01)
Net Income$-263,500,000.00
Net Margins-883.18%
Return on Equity-28.79%
Return on Assets-22.94%

Miscellaneous

Employees328
Outstanding Shares45,830,000

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) issued its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.68) by $0.05. The biotechnology company had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business's revenue was up 397.4% compared to the same quarter last year. During the same quarter last year, the business posted ($2.07) EPS. View bluebird bio's Earnings History.

When will bluebird bio make its next earnings announcement?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, February, 20th 2018. View Earnings Estimates for bluebird bio.

Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?

20 brokers have issued twelve-month price objectives for bluebird bio's stock. Their forecasts range from $71.00 to $215.00. On average, they anticipate bluebird bio's stock price to reach $149.47 in the next year. View Analyst Ratings for bluebird bio.

What are Wall Street analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:

  • 1. Cantor Fitzgerald analysts commented, "Renewed Confidence in SCD. We believe the longer-term HbA T87Q response of 6.4g/dL and 3.0g/dL achieved in Group B patients validates the improved process’ potential to address SCD. While long-term questions remain, especially as they pertain to sourcing of the drug product from peripheral blood, the updated clinical data lift a key uncertainty on the ability to achieve sufficient vector copy number (VCN) in peripheral blood translating into adequate healthy hemoglobin production, Additionally, the first Group C patient treated with an improved drug product and optimized cell source has demonstrated initial 1-month peripheral VCN of 2.5 copies/diploid, resembling results of the better performing Group B patient." (12/11/2017)
  • 2. Maxim Group analysts commented, "The approvals of Yescarta and Kymriah combined with Gilead’s acquisition of Kite have ushered in a paradigm shift in oncology. T- cell therapies (CAR- T, TCR, other) are here to stay. We attended the GE Manufacturing summit in Beijing (Cell Therapy Regulatory & Technology") earlier this month and it became evident that manufacturing obstacles will be overcome. The days of Dendreon’s debacle are long past. Remember too that gene therapy is not far behind as Spark’s Luxterna is expected to be approved in January 2018 with a seven-figure price tag." (11/30/2017)
  • 3. Morgan Stanley analysts commented, "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded Bluebird's stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to "increase investor confidence" in its sickle cell gene therapy."Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially," the analyst explained. "We do not believe the evidence supports current investor optimism that this can be solved by ASH." (10/2/2017)
  • 4. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (7/18/2017)
  • 5. BTIG Research analysts commented, "generally captured" data updates from ASCO and EHA. Positive On Outlook But Not Enough To Remain BullishMeanwhile, Bluebird has a "good lead" over the competition in drugs targeting anti-BCMA and a Phase 1 study of bb21217 will commence in the bottom half of 2017. But at the same time competitive efforts from rivals will also ramp up, including Kite Pharma Inc (NASDAQ: KITE), which will begin a study of a fully-human anti-BCMA CAR T therapy in the third quarter.The analyst remains "more optimistic than most" regarding the LentiGlobin program for Beta-thalassemia and Sickle-cell disease. Also, the company's broadening of its oncology efforts may be a source of concern among some investors but early success in bb2121 is indeed supportive of a "broader effort in larger markets with better defined patient populations." (6/30/2017)

Who are some of bluebird bio's key competitors?

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:

  • Daniel S. Lynch, Independent Chairman of the Board (Age 59)
  • Nick Leschly, President, Chief Executive Officer, Director (Age 44)
  • Jeffrey T. Walsh, Chief Financial and Strategy Officer and Principal Financial Officer, Principal Accounting Officer (Age 51)
  • Susanna Gatti High, Chief Operating Officer (Age 49)
  • Philip D. Gregory Ph.D., Chief Scientific Officer (Age 46)
  • David M. Davidson M.D., Chief Medical Officer (Age 53)
  • Jason F. Cole Esq., Chief Legal Officer, Secretary (Age 44)
  • John O. Agwunobi M.D., Director (Age 52)
  • Mary Lynne Hedley Ph.D., Director (Age 54)
  • Douglas A. Melton, Director

Who owns bluebird bio stock?

bluebird bio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.67%), Victory Capital Management Inc. (1.66%), Jennison Associates LLC (1.45%), Orbimed Advisors LLC (1.05%), Ameriprise Financial Inc. (0.74%) and Schwab Charles Investment Management Inc. (0.58%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.

Who sold bluebird bio stock? Who is selling bluebird bio stock?

bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Jennison Associates LLC, Baillie Gifford & Co., Pictet Asset Management Ltd., Wells Fargo & Company MN, Candriam Luxembourg S.C.A., New York State Common Retirement Fund and Emerald Advisers Inc. PA. Company insiders that have sold bluebird bio company stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Insider Buying and Selling for bluebird bio.

Who bought bluebird bio stock? Who is buying bluebird bio stock?

bluebird bio's stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., American Century Companies Inc., Schwab Charles Investment Management Inc., Frontier Capital Management Co. LLC, Orbimed Advisors LLC, Columbus Circle Investors, Dimensional Fund Advisors LP and Mitsubishi UFJ Trust & Banking Corp. View Insider Buying and Selling for bluebird bio.

How do I buy bluebird bio stock?

Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of bluebird bio stock can currently be purchased for approximately $201.80.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $9.23 billion and generates $6.16 million in revenue each year. The biotechnology company earns $-263,500,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. bluebird bio employs 328 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 Binney St, CAMBRIDGE, MA 02142-1512, United States. The biotechnology company can be reached via phone at +1-339-4999300 or via email at [email protected]


MarketBeat Community Rating for bluebird bio (BLUE)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  627 (Vote Outperform)
Underperform Votes:  238 (Vote Underperform)
Total Votes:  865
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

bluebird bio (NASDAQ:BLUE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.642.572.522.72
Ratings Breakdown: 2 Sell Rating(s)
4 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $145.48$131.70$107.33$98.73
Price Target Upside: 15.00% downside16.89% downside15.15% downside11.88% downside

bluebird bio (NASDAQ:BLUE) Consensus Price Target History

Price Target History for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ:BLUE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017BMO Capital MarketsSet Price TargetBuy$215.00HighView Rating Details
12/11/2017Jefferies GroupUpgradeHold -> Buy$130.00 -> $211.00HighView Rating Details
12/11/2017Cantor FitzgeraldSet Price TargetUnderweight -> Underweight$58.00 -> $113.00HighView Rating Details
12/5/2017Canaccord GenuityInitiated CoverageBuy -> Buy$202.00LowView Rating Details
11/30/2017Maxim GroupBoost Price TargetBuy -> Buy$170.00 -> $200.00HighView Rating Details
11/3/2017SunTrust BanksBoost Price TargetBuy -> Buy$108.00 -> $163.00N/AView Rating Details
11/3/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
11/2/2017BarclaysBoost Price TargetOverweight$151.00 -> $162.00N/AView Rating Details
11/2/2017WedbushReiterated RatingOutperform$135.00 -> $174.00N/AView Rating Details
11/2/2017BTIG ResearchUpgradeNeutral -> Buy$177.00N/AView Rating Details
11/1/2017Leerink SwannReiterated RatingOutperform$145.00 -> $162.00N/AView Rating Details
10/16/2017Evercore ISIUpgradeIn-Line -> Outperform$102.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingBuy -> Buy$186.00N/AView Rating Details
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform -> Outperform$134.00 -> $158.00MediumView Rating Details
8/31/2017CowenReiterated RatingOutperformHighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$109.00HighView Rating Details
6/26/2017Janney Montgomery ScottSet Price TargetBuy$125.00N/AView Rating Details
6/16/2017Standpoint ResearchReiterated RatingBuy -> Reduce$110.00LowView Rating Details
6/5/2017Bank of AmericaReiterated RatingHold$95.00HighView Rating Details
2/23/2017Roth CapitalSet Price TargetHold$71.00N/AView Rating Details
12/7/2016J P Morgan Chase & CoReiterated RatingBuy$120.00N/AView Rating Details
11/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

bluebird bio (NASDAQ:BLUE) Earnings History and Estimates Chart

Earnings by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ BLUE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018($1.68)N/AView Earnings Details
11/1/2017Q3 2017($1.68)($1.73)$8.47 million$7.71 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.66)($1.73)$6.29 million$16.70 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.76)($1.68)$1.51 million$6.83 millionViewN/AView Earnings Details
2/22/2017Q4 2016($1.86)($1.88)$1.76 million$1.55 millionViewN/AView Earnings Details
11/2/2016Q3 2016($1.59)($2.07)$1.82 million$1.55 millionViewN/AView Earnings Details
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
11/4/2015Q3($0.96)($1.18)$5.63 million$1.30 millionViewListenView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.68)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.62)($0.66)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.52)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)ViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

bluebird bio (NASDAQ:BLUE) Earnings Estimates

2017 EPS Consensus Estimate: ($7.19)
2018 EPS Consensus Estimate: ($6.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($1.88)($1.79)($1.83)
Q2 20175($1.89)($1.60)($1.75)
Q3 20175($1.94)($1.73)($1.80)
Q4 20175($2.03)($1.71)($1.81)
Q1 20181($1.68)($1.68)($1.68)
Q2 20181($1.66)($1.66)($1.66)
Q3 20181($1.73)($1.73)($1.73)
Q4 20181($1.76)($1.76)($1.76)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for bluebird bio (NASDAQ:BLUE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

bluebird bio (NASDAQ BLUE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)
Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ BLUE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Philip D GregoryInsiderSell2,250$172.54$388,215.00View SEC Filing  
12/1/2017Susanna Gatti HighCOOSell1,282$172.15$220,696.30View SEC Filing  
11/10/2017Jeffrey T WalshInsiderSell9,900$149.58$1,480,842.00View SEC Filing  
11/1/2017Jeffrey T WalshInsiderSell35,000$151.38$5,298,300.00View SEC Filing  
11/1/2017Nick LeschlyCEOSell2,127$145.17$308,776.59View SEC Filing  
10/23/2017Nick LeschlyInsiderSell7,050$145.14$1,023,237.00View SEC Filing  
10/20/2017Nick LeschlyCEOSell3,350$145.02$485,817.00View SEC Filing  
10/17/2017Nick LeschlyCEOSell10,823$145.05$1,569,876.15View SEC Filing  
10/10/2017Jeffrey T WalshInsiderSell4,900$129.94$636,706.00View SEC Filing  
10/2/2017David DavidsonInsiderSell4,000$131.31$525,240.00View SEC Filing  
9/14/2017John MaraganoreDirectorSell18,868$131.21$2,475,670.28View SEC Filing  
9/12/2017Mark VachonDirectorSell6,000$126.82$760,920.00View SEC Filing  
9/11/2017Jeffrey T WalshInsiderSell4,900$125.73$616,077.00View SEC Filing  
9/1/2017Nick LeschlyInsiderSell46,833$122.27$5,726,270.91View SEC Filing  
8/31/2017Daniel LynchDirectorSell500$120.00$60,000.00View SEC Filing  
8/31/2017Jeffrey T WalshInsiderSell12,000$125.01$1,500,120.00View SEC Filing  
8/30/2017Nick LeschlyInsiderSell25,667$115.18$2,956,325.06View SEC Filing  
8/28/2017Jeffrey T WalshInsiderSell1,250$107.06$133,825.00View SEC Filing  
8/14/2017James MandellDirectorSell1,000$95.95$95,950.00View SEC Filing  
8/10/2017Jeffrey T WalshInsiderSell1,250$95.41$119,262.50View SEC Filing  
8/7/2017Philip D GregoryInsiderSell750$99.00$74,250.00View SEC Filing  
8/4/2017Eric SullivanInsiderSell861$93.83$80,787.63View SEC Filing  
8/1/2017David DavidsonInsiderSell3,000$92.37$277,110.00View SEC Filing  
7/10/2017Jeffrey T WalshInsiderSell2,500$99.89$249,725.00View SEC Filing  
7/7/2017David DavidsonInsiderSell1,200$100.49$120,588.00View SEC Filing  
7/6/2017Philip D GregoryInsiderSell2,250$103.83$233,617.50View SEC Filing  
7/5/2017David DavidsonInsiderSell5,000$105.28$526,400.00View SEC Filing  
6/29/2017Eric SullivanInsiderSell6,787$108.96$739,511.52View SEC Filing  
6/27/2017Nick LeschlyInsiderSell25,000$108.05$2,701,250.00View SEC Filing  
6/23/2017Daniel LynchDirectorSell4,000$109.09$436,360.00View SEC Filing  
6/20/2017Daniel LynchDirectorSell2,500$120.03$300,075.00View SEC Filing  
6/7/2017Jason ColeInsiderSell17,245$100.22$1,728,293.90View SEC Filing  
6/6/2017Daniel LynchDirectorSell2,263$100.14$226,616.82View SEC Filing  
6/6/2017Philip D GregoryInsiderSell1,500$99.04$148,560.00View SEC Filing  
6/5/2017David DavidsonInsiderSell1,000$90.00$90,000.00View SEC Filing  
5/25/2017Daniel LynchDirectorSell2,000$80.00$160,000.00View SEC Filing  
4/27/2017Daniel LynchDirectorSell1,000$90.01$90,010.00View SEC Filing  
4/25/2017Daniel LynchDirectorSell2,000$86.75$173,500.00View SEC Filing  
4/10/2017Jeffrey T WalshInsiderSell1,250$87.38$109,225.00View SEC Filing  
4/3/2017David DavidsonInsiderSell3,000$90.89$272,670.00View SEC Filing  
3/27/2017Daniel LynchDirectorSell3,000$88.12$264,360.00View SEC Filing  
3/16/2017Daniel LynchDirectorSell237$100.07$23,716.59View SEC Filing  
3/16/2017Jason ColeInsiderSell4,930$100.07$493,345.10View SEC Filing  
3/3/2017John MaraganoreDirectorSell13,839$85.02$1,176,591.78View SEC Filing  
2/15/2017Daniel LynchDirectorSell150$80.22$12,033.00View SEC Filing  
2/15/2017Jason ColeInsiderSell666$80.22$53,426.52View SEC Filing  
2/14/2017Daniel LynchDirectorSell850$80.01$68,008.50View SEC Filing  
2/14/2017Jason ColeInsiderSell3,772$80.01$301,797.72View SEC Filing  
1/31/2017James MandellDirectorSell8,000$75.04$600,320.00View SEC Filing  
1/27/2017Daniel LynchDirectorSell1,000$70.09$70,090.00View SEC Filing  
1/27/2017David DavidsonInsiderSell6,000$69.02$414,120.00View SEC Filing  
1/5/2017Jason ColeInsiderSell549$67.10$36,837.90View SEC Filing  
10/3/2016Eric SullivanInsiderSell416$67.00$27,872.00View SEC Filing  
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.12View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.28View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.00View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.12View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.00View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.00View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.00View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.00View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.00View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

bluebird bio (NASDAQ BLUE) News Headlines

Source:
DateHeadline
Bluebird Bio Becoming Household Name With This Promising Cancer TreatmentBluebird Bio Becoming Household Name With This Promising Cancer Treatment
www.thestreet.com - December 11 at 5:15 PM
Bluebird Bio Inc. (BLUE) Has Leaped To A New High On Study ResultsBluebird Bio Inc. (BLUE) Has Leaped To A New High On Study Results
www.nasdaq.com - December 11 at 5:15 PM
11 Biotech Stocks Moving From ASH 201711 Biotech Stocks Moving From ASH 2017
www.msn.com - December 11 at 5:15 PM
BRIEF-Bluebird Bio Announces Proposed Public Offering Of Common StockBRIEF-Bluebird Bio Announces Proposed Public Offering Of Common Stock
www.reuters.com - December 11 at 5:15 PM
Life-Shortening Blood Disease Gets Rush of Gene-Based ResearchLife-Shortening Blood Disease Gets Rush of Gene-Based Research
finance.yahoo.com - December 11 at 5:15 PM
Goldman: Bluebird Bio Is One Step Closer To A Sickle Cell CureGoldman: Bluebird Bio Is One Step Closer To A Sickle Cell Cure
finance.yahoo.com - December 11 at 5:15 PM
bluebird bio Announces Proposed Public Offering of Common Stockbluebird bio Announces Proposed Public Offering of Common Stock
finance.yahoo.com - December 11 at 5:15 PM
Bluebird Bio stock retreats from records after announcing stock offeringBluebird Bio stock retreats from records after announcing stock offering
finance.yahoo.com - December 11 at 5:15 PM
bluebird bio Presents New Data from Clinical Studies of LentiGlobin™ Gene Therapy in Transfusion-Dependent β ... - Business Wire (press release)bluebird bio Presents New Data from Clinical Studies of LentiGlobin™ Gene Therapy in Transfusion-Dependent β ... - Business Wire (press release)
www.businesswire.com - December 11 at 10:33 AM
bluebird bio (BLUE) Reports Updated Data from HGB-205 Study of LentiGlobinTM Gene Therapy - StreetInsider.combluebird bio (BLUE) Reports Updated Data from HGB-205 Study of LentiGlobinTM Gene Therapy - StreetInsider.com
www.streetinsider.com - December 11 at 10:33 AM
Celgene (CELG) & bluebird bio (BLUE) Report Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 ... - StreetInsider.comCelgene (CELG) & bluebird bio (BLUE) Report Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 ... - StreetInsider.com
www.streetinsider.com - December 11 at 10:33 AM
After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target - BenzingaAfter Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target - Benzinga
www.benzinga.com - December 11 at 10:33 AM
Despite Bluebird Bios 17% Rally, Another 55% Surge Could Be ComingDespite Bluebird Bio's 17% Rally, Another 55% Surge Could Be Coming
finance.yahoo.com - December 11 at 10:33 AM
bluebird bio (BLUE) Upgraded to "Buy" by Jefferies Groupbluebird bio (BLUE) Upgraded to "Buy" by Jefferies Group
www.americanbankingnews.com - December 11 at 9:00 AM
bluebird bio (BLUE) PT Raised to $309.00 at Goldman Sachs Groupbluebird bio (BLUE) PT Raised to $309.00 at Goldman Sachs Group
www.americanbankingnews.com - December 11 at 9:00 AM
BMO Capital Markets Increases bluebird bio (BLUE) Price Target to $215.00BMO Capital Markets Increases bluebird bio (BLUE) Price Target to $215.00
www.americanbankingnews.com - December 11 at 9:00 AM
Analyzing bluebird bio (BLUE) & Its CompetitorsAnalyzing bluebird bio (BLUE) & Its Competitors
www.americanbankingnews.com - December 10 at 7:22 PM
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual MeetingCelgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
finance.yahoo.com - December 10 at 5:15 PM
bluebird bio Presents New Data from Clinical Studies of LentiGlobin™ Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meetingbluebird bio Presents New Data from Clinical Studies of LentiGlobin™ Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting
finance.yahoo.com - December 10 at 5:15 PM
bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin™ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meetingbluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin™ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - December 10 at 5:15 PM
Celgene up 3% ahead of ASH presentations - Seeking AlphaCelgene up 3% ahead of ASH presentations - Seeking Alpha
seekingalpha.com - December 9 at 9:48 AM
Contrasting bluebird bio (BLUE) and Its CompetitorsContrasting bluebird bio (BLUE) and Its Competitors
www.americanbankingnews.com - December 8 at 5:36 AM
bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell ... - Business Wire (press release)bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell ... - Business Wire (press release)
www.businesswire.com - December 7 at 5:26 PM
bluebird bio: This Winner Has A Bright 2018 Outlook - Seeking Alphabluebird bio: This Winner Has A Bright 2018 Outlook - Seeking Alpha
seekingalpha.com - December 7 at 5:26 PM
BRIEF-bluebird bio And TC BioPharm Announce Strategic CollaborationBRIEF-bluebird bio And TC BioPharm Announce Strategic Collaboration
www.reuters.com - December 7 at 10:04 AM
Here's Why bluebird bio's Shares Soared 24% in NovemberHere's Why bluebird bio's Shares Soared 24% in November
finance.yahoo.com - December 7 at 10:04 AM
bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapybluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy
finance.yahoo.com - December 7 at 10:04 AM
bluebird bio, Inc. (BLUE) COO Sells $220,696.30 in Stockbluebird bio, Inc. (BLUE) COO Sells $220,696.30 in Stock
www.americanbankingnews.com - December 5 at 6:48 PM
bluebird bio, Inc. (BLUE) Insider Philip D. Gregory Sells 2,250 Sharesbluebird bio, Inc. (BLUE) Insider Philip D. Gregory Sells 2,250 Shares
www.americanbankingnews.com - December 5 at 6:20 PM
Bluebird Bio (BLUE) Bullish Camp Just Got StrongerBluebird Bio (BLUE) Bullish Camp Just Got Stronger
finance.yahoo.com - December 5 at 10:30 AM
bluebird bio (BLUE) Earns Buy Rating from Analysts at Canaccord Genuitybluebird bio (BLUE) Earns Buy Rating from Analysts at Canaccord Genuity
www.americanbankingnews.com - December 5 at 9:46 AM
Maxim Group Analysts Give bluebird bio (BLUE) a $200.00 Price TargetMaxim Group Analysts Give bluebird bio (BLUE) a $200.00 Price Target
www.americanbankingnews.com - November 30 at 12:42 PM
bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to ... - Business Wire (press release)bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to ... - Business Wire (press release)
www.businesswire.com - November 29 at 5:25 PM
BRIEF-Bluebird Bio Acquires Manufacturing Facility In North CarolinaBRIEF-Bluebird Bio Acquires Manufacturing Facility In North Carolina
www.reuters.com - November 29 at 9:54 AM
A Virus Shortage? BlueBird Bio Buys A Factory To Make Its OwnA Virus Shortage? BlueBird Bio Buys A Factory To Make Its Own
finance.yahoo.com - November 29 at 9:54 AM
bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patientsbluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients
finance.yahoo.com - November 29 at 9:54 AM
ETFs with exposure to bluebird bio, Inc. : November 27, 2017ETFs with exposure to bluebird bio, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 6:31 PM
bluebird bio, Inc. (BLUE) Receives Consensus Rating of "Buy" from Brokeragesbluebird bio, Inc. (BLUE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 27 at 10:58 AM
bluebird bio, Inc. (BLUE) Receives Consensus Rating of "Buy" from Analystsbluebird bio, Inc. (BLUE) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 27 at 10:58 AM
bluebird bio, Inc. (BLUE) Given Average Recommendation of "Buy" by Brokeragesbluebird bio, Inc. (BLUE) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 27 at 10:58 AM
bluebird bio, Inc. (BLUE) Expected to Announce Quarterly Sales of $7.58 Millionbluebird bio, Inc. (BLUE) Expected to Announce Quarterly Sales of $7.58 Million
www.americanbankingnews.com - November 24 at 2:36 AM
bluebird bio, Inc. (BLUE) Expected to Announce Earnings of -$1.59 Per Sharebluebird bio, Inc. (BLUE) Expected to Announce Earnings of -$1.59 Per Share
www.americanbankingnews.com - November 22 at 11:10 PM
Maxim Group Analysts Give bluebird bio, Inc. (BLUE) a $170.00 Price TargetMaxim Group Analysts Give bluebird bio, Inc. (BLUE) a $170.00 Price Target
www.americanbankingnews.com - November 18 at 8:48 AM
Celgene CAR-T Therapy Gets Breakthrough Therapy DesignationCelgene CAR-T Therapy Gets Breakthrough Therapy Designation
www.nasdaq.com - November 17 at 7:47 PM
bluebird bio (BLUE) Says First Patient Treated in Northstar-3, Phase 3 Study of LentiGlobin in Patients with TDTbluebird bio (BLUE) Says First Patient Treated in Northstar-3, Phase 3 Study of LentiGlobin in Patients with TDT
www.streetinsider.com - November 17 at 7:47 PM
ETFs with exposure to bluebird bio, Inc. : November 16, 2017ETFs with exposure to bluebird bio, Inc. : November 16, 2017
finance.yahoo.com - November 17 at 7:47 PM
bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients ... - Business Wire (press release)bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients ... - Business Wire (press release)
www.businesswire.com - November 16 at 12:04 PM
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted ... - Business Wire (press release)Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted ... - Business Wire (press release)
www.businesswire.com - November 16 at 12:04 PM
bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotypebluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype
finance.yahoo.com - November 16 at 12:04 PM
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple MyelomaCelgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma
finance.yahoo.com - November 16 at 12:04 PM

SEC Filings

bluebird bio (NASDAQ:BLUE) SEC Filings

DateFilerForm TypeView
12/11/2017
4:03 PM
bluebird bio (Filer)
Form 424B5
View Filing
12/11/2017
8:15 AM
bluebird bio (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing
12/07/2017
7:05 AM
bluebird bio (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing
12/05/2017
3:09 PM
bluebird bio (Issuer)
HIGH SUSANNA GATTI (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/05/2017
3:08 PM
bluebird bio (Issuer)
Gregory Philip D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/05/2017
3:08 PM
bluebird bio (Issuer)
Davidson David (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
11/29/2017
7:05 AM
bluebird bio (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing

Social Media

Financials

bluebird bio (NASDAQ:BLUE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

bluebird bio (NASDAQ BLUE) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.